All In Biotech

NDA 216387 · Astrazeneca

Calquence

Acalabrutinib Maleate · Oral · Kinase Inhibitor

Accelerated approvalOrphan

Last checked: Nov 20, 2026Latest source record: Feb 19, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Aug 3, 2022

Approved uses

4

Original approval plus efficacy supplements

Registered trials

168

23 Phase 3, 38 recruiting

FAERS reports

12,744

10,675 serious, 2,699 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 19, 2026.

CALQUENCE is a kinase inhibitor indicated: • In combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation (HSCT). (1.1 ) • For the treatment of adult patients with MCL who have received at least one prior therapy. ( 1.2 ) • For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ( 1.3 ) 1.1 Previously Untreated Mantle Cell Lymphoma CALQUENCE in combination with bendamustine and rituximab is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation (HSCT). 1.2 Previously Treated Mantle Cell Lymphoma CALQUENCE is indicated for the treatment of adult patients with MCL who have received at least one prior therapy. 1.3 Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma CALQUENCE is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Mechanism: Acalabrutinib is a small-molecule inhibitor of Bruton tyrosine kinase (BTK). Acalabrutinib and its active metabolite, ACP-5862, form a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity. BTK is a signaling molecule of the B cell antigen receptor (BCR) and cytokine receptor pathways. In B cells, BTK signaling results in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion. In nonclinical studies, acalabrutinib inhibited BTK‑mediated activation of downstream signaling proteins CD86 and CD69...

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 19, 2026 Supplement 6 · Efficacy OrphanLetterLabel
  • Jan 16, 2025 Supplement 5 · Efficacy · priority review OrphanLabelLetter
  • Aug 3, 2022 Original approval · Type 3 - New Dosage Form Accelerated approvalOrphanLabelReview
  • Aug 3, 2022 Original approval · Type 3 - New Dosage Form OrphanLetterLabelReview
1 products under this application
  • CALQUENCE · ACALABRUTINIB MALEATE EQ 100MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Acalabrutinib" as an intervention, any sponsor and status, largest first.

All 168 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death2,186
  • fatigue725
  • headache657
  • product dose omission issue522
  • diarrhoea443
  • fall395
  • dyspnoea352
  • contusion351
  • pneumonia337
  • malignant neoplasm progression325
  • asthenia314
  • pain302

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20161
201744
2018193
2019198
2020588
20211,080
20221,443
20232,240
20242,719
20252,330
20261,908

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Calquence (Acalabrutinib)

2024 spending

$564K

Beneficiaries

18

41 claims

Per beneficiary

$31,341

$231.11 per unit

View as table
YearSpending
2020$349,971,873
2021$774,700,145
2022$1,028,537,752
2023$59,763,180
2024$564,130

Part D: Calquence (Acalabrutinib Maleate)

2024 spending

$1.70B

Beneficiaries

15,056

122,356 claims

Per beneficiary

$113,043

$248.67 per unit

View as table
YearSpending
2020$0
2021$0
2022$164,376,683
2023$1,286,819,830
2024$1,701,974,921

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 100 on PubMed

Sponsor: AstraZeneca

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.